COVID-19 Genetic Engineering Articles from The Lancet
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
COVID-19 Genetic Engineering Articles from Nature Biotechnology
COVID-19 Genetic Engineering Articles from The New England Journal of Medicine
COVID-19 Genetic Engineering Articles from The Lancet
COVID-19 Genetic Engineering Articles from Virologica Sinica
COVID-19 Genetic Engineering Articles from medRxiv
COVID-19 Genetic Engineering Articles from Asian Pacific Journal of Allergy and Immunology
COVID-19 Genetic Engineering Articles from Nature
COVID-19 Genetic Engineering Articles from Nature Nanotechnology
COVID-19 Science Translational Medicine Articles
COVID-19 Genetic Engineering from Nature
COVID-19 Genetic Engineering articles from Frontiers in Immunology
COVID-19 Genetic Engineering articles from European Journal of Pharmacology
Learn After
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.